Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Leukocyte Surface Antigen CD47 (Antigenic Surface Determint Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Overview
Leukocyte Surface Antigen CD47 (Antigenic Surface Determint Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Leukocyte Surface Antigen CD47 (Antigenic Surface Determint Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Leukocyte Surface Antigen CD47 (Antigenic Surface Determint Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Companies Involved in Therapeutics Development
Abpro Corp
ALX Oncology Inc
Arch Oncology Inc
Aurigene Discovery Technologies Ltd
Beijing Hanmi Pharmaceutical Co Ltd
Biocad
Bristol-Myers Squibb Co
EpicentRx Inc
Forty Seven Inc
GeneScience Pharmaceuticals Co Ltd
GigaGen Inc
Hummingbird Bioscience Pte Ltd
I-Mab Biopharma Co Ltd
ImmuneOncia Therapeutics LLC
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
Innovent Biologics Inc
Jiangsu Hengrui Medicine Co Ltd
KAHR medical Ltd
LynkCell Inc
MesaGen LLC
NovImmune SA
Opsyon
Paradigm Shift Therapeutics LLC
Phanes Therapeutics Inc
PharmAbcine Inc
Shanghai Henlius Biotech Inc
Sorrento Therapeutics Inc
Surface Oncology Inc
Synthon Holdings BV
TOT Biopharm Co Ltd
Trillium Therapeutics Inc
Waterstone Hanxbio Pty Ltd
Leukocyte Surface Antigen CD47 (Antigenic Surface Determint Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Drug Profiles
ABP-160 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALX-148 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Appendix



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1)
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Abpro Corp, H2 2019
Pipeline by ALX Oncology Inc, H2 2019
Pipeline by Arch Oncology Inc, H2 2019
Pipeline by Aurigene Discovery Technologies Ltd, H2 2019
Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2019
Pipeline by Biocad, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by EpicentRx Inc, H2 2019
Pipeline by Forty Seven Inc, H2 2019
Pipeline by GeneScience Pharmaceuticals Co Ltd, H2 2019
Pipeline by GigaGen Inc, H2 2019
Pipeline by Hummingbird Bioscience Pte Ltd, H2 2019
Pipeline by I-Mab Biopharma Co Ltd, H2 2019
Pipeline by ImmuneOncia Therapeutics LLC, H2 2019
Pipeline by ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd, H2 2019
Pipeline by Innovent Biologics Inc, H2 2019
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019
Pipeline by KAHR medical Ltd, H2 2019
Pipeline by LynkCell Inc, H2 2019
Pipeline by MesaGen LLC, H2 2019
Pipeline by NovImmune SA, H2 2019
Pipeline by Opsyon, H2 2019
Pipeline by Paradigm Shift Therapeutics LLC, H2 2019
Pipeline by Phanes Therapeutics Inc, H2 2019
Pipeline by PharmAbcine Inc, H2 2019
Pipeline by Shanghai Henlius Biotech Inc, H2 2019
Pipeline by Sorrento Therapeutics Inc, H2 2019
Pipeline by Surface Oncology Inc, H2 2019
Pipeline by Synthon Holdings BV, H2 2019
Pipeline by TOT Biopharm Co Ltd, H2 2019
Pipeline by Trillium Therapeutics Inc, H2 2019
Pipeline by Waterstone Hanxbio Pty Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019